Merck & Company, Inc. Press Releases

MRK 
$55.51
*  
0.38
0.69%
Get MRK Alerts
*Delayed - data as of Oct. 22, 2014  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
GNS Healthcare Expands Executive Team with Addition of Three Industry Veterans
10/20/2014 8:55:00 AM - Business Wire


Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
10/20/2014 8:00:00 AM - PR Newswire
▲2.70 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
10/20/2014 8:00:00 AM - Business Wire
▲2.70 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Final Results of Tender Offers for Eight Series of Notes
10/15/2014 8:00:00 AM - Business Wire
▼-1.18 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Pricing of Tender Offers for Eight Series of Notes
10/14/2014 6:20:00 PM - Business Wire
▼-1.46 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting
10/8/2014 11:13:00 AM - Business Wire


Merck Prices EUR 2.5 Billion Debt Offering
10/6/2014 12:28:00 PM - Business Wire


Merck Announces Proposed Public Debt Offering
10/6/2014 3:24:00 AM - Business Wire


Merck Announces Tender Offers for Eight Series of Notes
10/6/2014 3:18:00 AM - Business Wire


Merck Congratulates Ecuador as Second Country to Receive PAHO/WHO Verification of Elimination of River Blindness
10/3/2014 9:00:00 AM - Business Wire


Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion
10/1/2014 11:30:00 AM - Business Wire


Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion
10/1/2014 11:30:00 AM - Business Wire


MSD Announces First Presentation of Early Data on the Investigational Use of Pembrolizumab in Patients with Advanced Bladder Cancer at ESMO 2014
9/29/2014 5:00:00 AM - Business Wire


Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
9/29/2014 5:00:00 AM - Business Wire


MSD Announces First Presentation of Data on the Investigational Use of Pembrolizumab in Patients with Advanced Gastric Cancer at ESMO 2014
9/28/2014 3:15:00 AM - Business Wire


Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014
9/28/2014 3:15:00 AM - Business Wire


Merck to Hold Third-Quarter 2014 Sales and Earnings Conference Call on October 27
9/24/2014 5:00:00 PM - Business Wire


Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry
9/22/2014 6:28:00 AM - Business Wire


Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
9/19/2014 11:00:00 AM - PR Newswire


Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
9/17/2014 9:31:00 AM - Business Wire


Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
9/17/2014 8:30:00 AM - Business Wire


Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
9/15/2014 1:30:00 PM - Business Wire


Four New Partner Organizations Join Optum Labs Research Collaborative
9/9/2014 8:00:00 AM - Business Wire


Merck to Participate at the Morgan Stanley Global Healthcare Conference
9/8/2014 5:00:00 PM - Business Wire


Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
9/4/2014 3:46:00 PM - PR Newswire